Company intelligence / Profile preview
National Vaccine & Serum Institute
- Ownership
- Private
- Employees
- ~7000
- Development stage
- Commercial
Overview
SII manufactures over a billion doses annually across more than two dozen WHO-prequalified vaccines. Its products are used in national immunization programs worldwide and have played key roles in global health initiatives such as polio eradication and COVID‑19 response. It supplies about two-thirds of the world’s children with at least one dose from its portfolio each year.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccines (live attenuated, inactivated, recombinant)Antisera/antitoxins (e.g., anti-snake venom serum)Monoclonal antibodies
- Industry
- Pharma
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on National Vaccine & Serum Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on National Vaccine & Serum Institute.